|
USA-CA-MONTEREYPARK Azienda Directories
|
Azienda News:
- Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 . . .
Results: Engagement with BCMA, GPRC5D and or CD38 resulted in multi-specific CAR-T cells exhibiting improved immune cell activation, increased degranulation upon activation, comparable or increased cytotoxicity and cytokine production, as well as enhanced target-dependent expansion under repetitive tumor challenges
- ASH 2024｜原启生物公布其创新型多靶点CAR-T针对晚期 . . .
为应对这些挑战，原启生物研发了具有新型结合域的多靶点CAR-T细胞，该结合域能同时靶向BCMA、GPRC5D和CD38，以提高在可溶性BCMA存在下对异质性或单抗原表达的MM细胞的敏感性和治疗效果，降低抗原逃逸的风险，并且确保对仅表达CD38的细胞无毒副作用。 此外，该产品还融入了一种新型“装甲”技术Ori，以恢复T细胞的适应性并提高其持久性，从而进一步增强了这种多靶点疗法的治疗潜力。 研究数据显示，这款多靶点CAR-T产品作为一种新型治疗方法，展现出了广阔且深入清除异质性多发性骨髓瘤细胞克隆和亚群的能力，为未来该领域的临床探索奠定了坚实基础，有望为初诊和复发 难治性MM患者带来持久且显著的治疗效果。
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in . . . - PubMed
Twenty-three patients with RRMM received infusions of BM38 CAR-Ts in a phase I trial Results: BM38 CAR-Ts showed stronger in vitro cytotoxicity to heterogeneous MM cells than did T cells expressing an individual BCMA or CD38 CAR BM38 CAR-Ts also exhibited potent antimyeloma activity in xenograft mouse models
- Bispecific antibodies targeting BCMA or GPRC5D are highly . . . - Nature
In the current study, we analyzed a large, international cohort of patients treated for relapse after BCMA-directed CAR T-cell therapies for TCE RRMM We aimed at identifying the most
- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple . . .
One can envision dual targeting of BCMA and GPRC5D in four different ways: (i) the parallel production of two mono-specific CAR T-cell populations that are coadministered or administered sequentially; (ii) genetically modifying T cells to coexpress two distinct CARs by transduction with individual viral vectors encoding each construct; (iii
- Oricell Therapeutics Announces Poster Presentation on Innovative Multi . . .
To address these challenges, Oricell has developed multi-specific CAR-Ts featuring novel binders targeting BCMA, GPRC5D, and CD38, to enhance sensitivity and efficacy toward heterogenous or single antigen expressing MM cells in the presence of soluble BCMA, mitigate the risk of antigen escape, and cause no toxicity towards the cells expressing
- Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 . . .
To address these challenges, we have developed multi-specific CAR-T targeting antigens - BCMA, GPRC5D and or CD38, and incorporating novel armor, in order to enhance anti-tumor efficacy in the presence of soluble BCMA (sBCMA), reduce risk of Ag escape, preserve T cell fitness and promote expansion
- Anti-BCMA GPRC5D bispecific CAR T cells in patients with relapsed or . . .
A preclinical study showed that CAR T-cell therapy targeting BCMA and GPRC5D could reduce relapse due to BCMA antigen loss and eliminate BCMA-negative multiple myeloma cells in mouse models
- Efficacy and safety of chimeric antigen receptor T cells targeting BCMA . . .
Background: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) to treat relapsed or refractory multiple myeloma (RRMM) In this study, we compared the efficacy and safety of BCMA
- 以BCMA和CD38为靶点的双特异性CAR-T细胞治疗复发 难治性 . . .
基于这一观察结果，本研究设计了一种第二代双特异性BM38-CAR，其中包含一种全人类抗BCMA单链可变片段（scFv）和一种人源化抗CD38-scFv。 CD38广泛且高表达于MM细胞，包括耐药的骨髓瘤起始细胞。 CD38靶向CAR-T在临床前研究中显示出抗MM活性。 CD38作为CAR靶点的主要问题是其在造血祖细胞（HPC）和正常T细胞上的弱表达，因此面临骨髓毒性和自相残杀的潜在风险。 通过亲和力优化建立了一种合理的策略，以减少脱靶效应，表达CD38定向的CARA4的T细胞（亲和力降低）可以选择性地消除CD38++MM细胞，但保留CD38+HPC和T细胞。 因此降低了BM38 CAR中抗CD38单链抗体的亲和力，并保持了抗BCMA单链抗体对主要细胞毒性的高亲和力。
|
|